Top Key Companies for Molecular Diagnostics (MDx) Point of Care Market: Abbott Laboratories, EKF Diagnostics, Becton Dickinson & Company, DxNA LLC, Trinity Biotech, Quidel Corporation, Luminex Corporation, Hologic Inc., Johnson & Johnson, Danaher Corporation, QIAGEN N.V, Mesa Biotech Inc., Siemens Healthineers, F. Hoffmann-La Roche AG, Roche Diagnostics.
Global Molecular Diagnostics (MDx) Point of Care Market Is Expected to Grow at A Significant Growth Rate, And the Forecast Period Is 2025-2032, Considering the Base Year As 2024.
Global Molecular Diagnostics (MDx) Point of Care Market Overview And Scope:
The Global Molecular Diagnostics (MDx) Point of Care Market Report 2025 provides comprehensive analysis of market development components, patterns, flows, and sizes. This research study of Molecular Diagnostics (MDx) Point of Care utilized both primary and secondary data sources to calculate present and past market values to forecast potential market management for the forecast period between 2025 and 2032. It includes the study of a wide range of industry parameters, including government policies, market environments, competitive landscape, historical data, current market trends, technological innovations, upcoming technologies, and technological progress within related industries. Additionally, the report provides an in-depth analysis of the value chain and supply chain to demonstrate how value is added at every stage in the product lifecycle. The study incorporates market dynamics such as drivers, restraints/challenges, trends, and their impact on the market.
Global Molecular Diagnostics (MDx) Point of Care Market Segmentation
By Type, Molecular Diagnostics (MDx) Point of Care market has been segmented into:
Isothermal Nucleic Acid Amplification Technology (INAAT)
Polymerase Chain Reaction (PCR)
Digital PCR
Real Time PCR
Others
By Application, Molecular Diagnostics (MDx) Point of Care market has been segmented into:
Infectious Diseases
Oncology
Hematology
Prenatal Testing
Endocrinology
Others
Regional Analysis of Molecular Diagnostics (MDx) Point of Care Market:
North America (U.S., Canada, Mexico)
Eastern Europe (Bulgaria, The Czech Republic, Hungary, Poland, Romania, Rest of Eastern Europe)
Western Europe (Germany, UK, France, Netherlands, Italy, Russia, Spain, Rest of Western Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Bahrain, Kuwait, Saudi Arabia, Qatar, UAE, Israel, South Africa)
Competitive Landscape of Molecular Diagnostics (MDx) Point of Care Market:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Molecular Diagnostics (MDx) Point of Care market study focused on including all the primary level, secondary level and tertiary level competitors in the report.The data generated by conducting the primary and secondary research. The report covers detail analysis of driver, constraints and scope for new players entering the Molecular Diagnostics (MDx) Point of Care market.
Top Key Companies Covered in Molecular Diagnostics (MDx) Point of Care market are:
Abbott Laboratories
EKF Diagnostics
Becton Dickinson & Company
DxNA LLC
Trinity Biotech
Quidel Corporation
Luminex Corporation
Hologic Inc.
Johnson & Johnson
Danaher Corporation
QIAGEN N.V
Mesa Biotech Inc.
Siemens Healthineers
F. Hoffmann-La Roche AG
Roche Diagnostics
Key Questions answered in the Molecular Diagnostics (MDx) Point of Care Market Report:
1. What is the expected Molecular Diagnostics (MDx) Point of Care Market size during the forecast period, 2025-2032?
2. Which region is the largest market for the Molecular Diagnostics (MDx) Point of Care Market?
3. What is the expected future scenario and the revenue generated by different regions and countries in the Molecular Diagnostics (MDx) Point of Care Market, such as North America, Europe, AsiaPacific & Japan, China, U.K., South America, and Middle East and Africa?
4. What is the competitive strength of the key players in the Molecular Diagnostics (MDx) Point of Care Market on the basis of the analysis of their recent developments, product offerings, and regional presence?
5. Where do the key Molecular Diagnostics (MDx) Point of Care companies lie in their competitive benchmarking compared to the factors of market coverage and market potential?
6. How are the adoption scenario, related opportunities, and challenges impacting the Molecular Diagnostics (MDx) Point of Care Markets?
7. How is the funding and investment landscape in the Molecular Diagnostics (MDx) Point of Care Market?
8. Which are the leading consortiums and associations in the Molecular Diagnostics (MDx) Point of Care Market, and what is their role in the market?
Research Methodology for Molecular Diagnostics (MDx) Point of Care Market Report:
The report presents a detailed assessment of the Molecular Diagnostics (MDx) Point of Care Market, along with qualitative inputs and insights from Company. This research study involved the extensive use of both primary and secondary sources.Various factors affecting the industry were studied to identify the segmentation types; industry trends; key players; competitive landscape of different products and services provided by separate market players;key market dynamics, such as drivers, restraints, opportunities, challenges, and industry trends; and key player strategies. Macroeconomic indicators and bottom-up and top-down approaches are used to arrive at a complete set of data points that give way to valuable qualitative and quantitative insights.Each data point is verified by the process of data triangulation to validate the numbers and arrive at close estimates.
Chapter 1: Introduction
1.1 Research Objectives
1.2 Research Methodology
1.3 Research Process
1.4 Scope and Coverage
1.4.1 Market Definition
1.4.2 Key Questions Answered
1.5 Market Segmentation
Chapter 2:Executive Summary
Chapter 3:Growth Opportunities By Segment
3.1 By Type
3.2 By Application
Chapter 4: Market Landscape
4.1 Porter's Five Forces Analysis
4.1.1 Bargaining Power of Supplier
4.1.2 Threat of New Entrants
4.1.3 Threat of Substitutes
4.1.4 Competitive Rivalry
4.1.5 Bargaining Power Among Buyers
4.2 Industry Value Chain Analysis
4.3 Market Dynamics
4.3.1 Drivers
4.3.2 Restraints
4.3.3 Opportunities
4.5.4 Challenges
4.4 Pestle Analysis
4.5 Technological Roadmap
4.6 Regulatory Landscape
4.7 SWOT Analysis
4.8 Price Trend Analysis
4.9 Patent Analysis
4.10 Analysis of the Impact of Covid-19
4.10.1 Impact on the Overall Market
4.10.2 Impact on the Supply Chain
4.10.3 Impact on the Key Manufacturers
4.10.4 Impact on the Pricing
Chapter 5: Molecular Diagnostics (MDx) Point of Care Market by Type
5.1 Molecular Diagnostics (MDx) Point of Care Market Overview Snapshot and Growth Engine
5.2 Molecular Diagnostics (MDx) Point of Care Market Overview
5.3 Isothermal Nucleic Acid Amplification Technology (INAAT)
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Isothermal Nucleic Acid Amplification Technology (INAAT): Geographic Segmentation
5.4 Polymerase Chain Reaction (PCR)
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Polymerase Chain Reaction (PCR): Geographic Segmentation
5.5 Digital PCR
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Digital PCR: Geographic Segmentation
5.6 Real Time PCR
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Real Time PCR: Geographic Segmentation
5.7 Others
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Others: Geographic Segmentation
Chapter 6: Molecular Diagnostics (MDx) Point of Care Market by Application
6.1 Molecular Diagnostics (MDx) Point of Care Market Overview Snapshot and Growth Engine
6.2 Molecular Diagnostics (MDx) Point of Care Market Overview
6.3 Infectious Diseases
6.3.1 Introduction and Market Overview
6.3.2 Historic and Forecasted Market Size (2017-2032F)
6.3.3 Key Market Trends, Growth Factors and Opportunities
6.3.4 Infectious Diseases: Geographic Segmentation
6.4 Oncology
6.4.1 Introduction and Market Overview
6.4.2 Historic and Forecasted Market Size (2017-2032F)
6.4.3 Key Market Trends, Growth Factors and Opportunities
6.4.4 Oncology: Geographic Segmentation
6.5 Hematology
6.5.1 Introduction and Market Overview
6.5.2 Historic and Forecasted Market Size (2017-2032F)
6.5.3 Key Market Trends, Growth Factors and Opportunities
6.5.4 Hematology: Geographic Segmentation
6.6 Prenatal Testing
6.6.1 Introduction and Market Overview
6.6.2 Historic and Forecasted Market Size (2017-2032F)
6.6.3 Key Market Trends, Growth Factors and Opportunities
6.6.4 Prenatal Testing: Geographic Segmentation
6.7 Endocrinology
6.7.1 Introduction and Market Overview
6.7.2 Historic and Forecasted Market Size (2017-2032F)
6.7.3 Key Market Trends, Growth Factors and Opportunities
6.7.4 Endocrinology: Geographic Segmentation
6.8 Others
6.8.1 Introduction and Market Overview
6.8.2 Historic and Forecasted Market Size (2017-2032F)
6.8.3 Key Market Trends, Growth Factors and Opportunities
6.8.4 Others: Geographic Segmentation
Chapter 7: Company Profiles and Competitive Analysis
7.1 Competitive Landscape
7.1.1 Competitive Positioning
7.1.2 Molecular Diagnostics (MDx) Point of Care Sales and Market Share By Players
7.1.3 Industry BCG Matrix
7.1.4 Heat Map Analysis
7.1.5 Molecular Diagnostics (MDx) Point of Care Industry Concentration Ratio (CR5 and HHI)
7.1.6 Top 5 Molecular Diagnostics (MDx) Point of Care Players Market Share
7.1.7 Mergers and Acquisitions
7.1.8 Business Strategies By Top Players
7.2 ABBOTT LABORATORIES
7.2.1 Company Overview
7.2.2 Key Executives
7.2.3 Company Snapshot
7.2.4 Operating Business Segments
7.2.5 Product Portfolio
7.2.6 Business Performance
7.2.7 Key Strategic Moves and Recent Developments
7.2.8 SWOT Analysis
7.3 EKF DIAGNOSTICS
7.4 BECTON DICKINSON & COMPANY
7.5 DXNA LLC
7.6 TRINITY BIOTECH
7.7 QUIDEL CORPORATION
7.8 LUMINEX CORPORATION
7.9 HOLOGIC INC.
7.10 JOHNSON & JOHNSON
7.11 DANAHER CORPORATION
7.12 QIAGEN N.V
7.13 MESA BIOTECH INC.
7.14 SIEMENS HEALTHINEERS
7.15 F. HOFFMANN-LA ROCHE AG
7.16 ROCHE DIAGNOSTICS
Chapter 8: Global Molecular Diagnostics (MDx) Point of Care Market Analysis, Insights and Forecast, 2017-2032
8.1 Market Overview
8.2 Historic and Forecasted Market Size By Type
8.2.1 Isothermal Nucleic Acid Amplification Technology (INAAT)
8.2.2 Polymerase Chain Reaction (PCR)
8.2.3 Digital PCR
8.2.4 Real Time PCR
8.2.5 Others
8.3 Historic and Forecasted Market Size By Application
8.3.1 Infectious Diseases
8.3.2 Oncology
8.3.3 Hematology
8.3.4 Prenatal Testing
8.3.5 Endocrinology
8.3.6 Others
Chapter 9: North America Molecular Diagnostics (MDx) Point of Care Market Analysis, Insights and Forecast, 2017-2032
9.1 Key Market Trends, Growth Factors and Opportunities
9.2 Impact of Covid-19
9.3 Key Players
9.4 Key Market Trends, Growth Factors and Opportunities
9.4 Historic and Forecasted Market Size By Type
9.4.1 Isothermal Nucleic Acid Amplification Technology (INAAT)
9.4.2 Polymerase Chain Reaction (PCR)
9.4.3 Digital PCR
9.4.4 Real Time PCR
9.4.5 Others
9.5 Historic and Forecasted Market Size By Application
9.5.1 Infectious Diseases
9.5.2 Oncology
9.5.3 Hematology
9.5.4 Prenatal Testing
9.5.5 Endocrinology
9.5.6 Others
9.6 Historic and Forecast Market Size by Country
9.6.1 US
9.6.2 Canada
9.6.3 Mexico
Chapter 10: Eastern Europe Molecular Diagnostics (MDx) Point of Care Market Analysis, Insights and Forecast, 2017-2032
10.1 Key Market Trends, Growth Factors and Opportunities
10.2 Impact of Covid-19
10.3 Key Players
10.4 Key Market Trends, Growth Factors and Opportunities
10.4 Historic and Forecasted Market Size By Type
10.4.1 Isothermal Nucleic Acid Amplification Technology (INAAT)
10.4.2 Polymerase Chain Reaction (PCR)
10.4.3 Digital PCR
10.4.4 Real Time PCR
10.4.5 Others
10.5 Historic and Forecasted Market Size By Application
10.5.1 Infectious Diseases
10.5.2 Oncology
10.5.3 Hematology
10.5.4 Prenatal Testing
10.5.5 Endocrinology
10.5.6 Others
10.6 Historic and Forecast Market Size by Country
10.6.1 Bulgaria
10.6.2 The Czech Republic
10.6.3 Hungary
10.6.4 Poland
10.6.5 Romania
10.6.6 Rest of Eastern Europe
Chapter 11: Western Europe Molecular Diagnostics (MDx) Point of Care Market Analysis, Insights and Forecast, 2017-2032
11.1 Key Market Trends, Growth Factors and Opportunities
11.2 Impact of Covid-19
11.3 Key Players
11.4 Key Market Trends, Growth Factors and Opportunities
11.4 Historic and Forecasted Market Size By Type
11.4.1 Isothermal Nucleic Acid Amplification Technology (INAAT)
11.4.2 Polymerase Chain Reaction (PCR)
11.4.3 Digital PCR
11.4.4 Real Time PCR
11.4.5 Others
11.5 Historic and Forecasted Market Size By Application
11.5.1 Infectious Diseases
11.5.2 Oncology
11.5.3 Hematology
11.5.4 Prenatal Testing
11.5.5 Endocrinology
11.5.6 Others
11.6 Historic and Forecast Market Size by Country
11.6.1 Germany
11.6.2 UK
11.6.3 France
11.6.4 Netherlands
11.6.5 Italy
11.6.6 Russia
11.6.7 Spain
11.6.8 Rest of Western Europe
Chapter 12: Asia Pacific Molecular Diagnostics (MDx) Point of Care Market Analysis, Insights and Forecast, 2017-2032
12.1 Key Market Trends, Growth Factors and Opportunities
12.2 Impact of Covid-19
12.3 Key Players
12.4 Key Market Trends, Growth Factors and Opportunities
12.4 Historic and Forecasted Market Size By Type
12.4.1 Isothermal Nucleic Acid Amplification Technology (INAAT)
12.4.2 Polymerase Chain Reaction (PCR)
12.4.3 Digital PCR
12.4.4 Real Time PCR
12.4.5 Others
12.5 Historic and Forecasted Market Size By Application
12.5.1 Infectious Diseases
12.5.2 Oncology
12.5.3 Hematology
12.5.4 Prenatal Testing
12.5.5 Endocrinology
12.5.6 Others
12.6 Historic and Forecast Market Size by Country
12.6.1 China
12.6.2 India
12.6.3 Japan
12.6.4 South Korea
12.6.5 Malaysia
12.6.6 Thailand
12.6.7 Vietnam
12.6.8 The Philippines
12.6.9 Australia
12.6.10 New Zealand
12.6.11 Rest of APAC
Chapter 13: Middle East & Africa Molecular Diagnostics (MDx) Point of Care Market Analysis, Insights and Forecast, 2017-2032
13.1 Key Market Trends, Growth Factors and Opportunities
13.2 Impact of Covid-19
13.3 Key Players
13.4 Key Market Trends, Growth Factors and Opportunities
13.4 Historic and Forecasted Market Size By Type
13.4.1 Isothermal Nucleic Acid Amplification Technology (INAAT)
13.4.2 Polymerase Chain Reaction (PCR)
13.4.3 Digital PCR
13.4.4 Real Time PCR
13.4.5 Others
13.5 Historic and Forecasted Market Size By Application
13.5.1 Infectious Diseases
13.5.2 Oncology
13.5.3 Hematology
13.5.4 Prenatal Testing
13.5.5 Endocrinology
13.5.6 Others
13.6 Historic and Forecast Market Size by Country
13.6.1 Turkey
13.6.2 Bahrain
13.6.3 Kuwait
13.6.4 Saudi Arabia
13.6.5 Qatar
13.6.6 UAE
13.6.7 Israel
13.6.8 South Africa
Chapter 14: South America Molecular Diagnostics (MDx) Point of Care Market Analysis, Insights and Forecast, 2017-2032
14.1 Key Market Trends, Growth Factors and Opportunities
14.2 Impact of Covid-19
14.3 Key Players
14.4 Key Market Trends, Growth Factors and Opportunities
14.4 Historic and Forecasted Market Size By Type
14.4.1 Isothermal Nucleic Acid Amplification Technology (INAAT)
14.4.2 Polymerase Chain Reaction (PCR)
14.4.3 Digital PCR
14.4.4 Real Time PCR
14.4.5 Others
14.5 Historic and Forecasted Market Size By Application
14.5.1 Infectious Diseases
14.5.2 Oncology
14.5.3 Hematology
14.5.4 Prenatal Testing
14.5.5 Endocrinology
14.5.6 Others
14.6 Historic and Forecast Market Size by Country
14.6.1 Brazil
14.6.2 Argentina
14.6.3 Rest of SA
Chapter 15 Investment Analysis
Chapter 16 Analyst Viewpoint and Conclusion
Molecular Diagnostics (MDx) Point of Care Scope:
|
Report Data
|
Molecular Diagnostics (MDx) Point of Care Market
|
|
Molecular Diagnostics (MDx) Point of Care Market Size in 2025
|
USD XX million
|
|
Molecular Diagnostics (MDx) Point of Care CAGR 2025 - 2032
|
XX%
|
|
Molecular Diagnostics (MDx) Point of Care Base Year
|
2024
|
|
Molecular Diagnostics (MDx) Point of Care Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Abbott Laboratories, EKF Diagnostics, Becton Dickinson & Company, DxNA LLC, Trinity Biotech, Quidel Corporation, Luminex Corporation, Hologic Inc., Johnson & Johnson, Danaher Corporation, QIAGEN N.V, Mesa Biotech Inc., Siemens Healthineers, F. Hoffmann-La Roche AG, Roche Diagnostics.
|
|
Key Segments
|
By Type
Isothermal Nucleic Acid Amplification Technology (INAAT) Polymerase Chain Reaction (PCR) Digital PCR Real Time PCR Others
By Applications
Infectious Diseases Oncology Hematology Prenatal Testing Endocrinology Others
|